What is HC Wainwright’s Estimate for DAWN Q1 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Thursday, October 31st. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.20) EPS.

Several other research analysts also recently commented on DAWN. Needham & Company LLC reissued a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. JPMorgan Chase & Co. decreased their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Piper Sandler reiterated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Finally, Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Stock Down 0.5 %

Shares of DAWN stock opened at $14.65 on Monday. The business has a fifty day simple moving average of $14.19 and a 200 day simple moving average of $14.39. The company has a market cap of $1.48 billion, a P/E ratio of -14.22 and a beta of -1.51. Day One Biopharmaceuticals has a twelve month low of $10.90 and a twelve month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same quarter in the previous year, the company earned ($0.54) earnings per share.

Insider Activity

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now directly owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now directly owns 1,097,535 shares of the company’s stock, valued at approximately $15,606,947.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 2,232 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the sale, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,748 shares of company stock worth $689,072 in the last quarter. 8.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DAWN. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares in the last quarter. SG Americas Securities LLC acquired a new position in Day One Biopharmaceuticals during the 2nd quarter valued at about $113,000. Point72 DIFC Ltd bought a new stake in Day One Biopharmaceuticals during the 2nd quarter worth approximately $124,000. Hsbc Holdings PLC purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter worth approximately $163,000. Finally, SteelPeak Wealth LLC bought a new position in shares of Day One Biopharmaceuticals in the second quarter valued at approximately $218,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.